Additional File 3 of Characterization and Application of a Lactate and Branched Chain Amino Acid Metabolism Related Gene Signature in a Prognosis Risk Model for Multiple Myeloma

Zhengyu Yu,Bingquan Qiu,Huapeng Zhou,Linfeng Li,Ting Niu

DOI: https://doi.org/10.6084/m9.figshare.23949598

2023-01-01

Abstract:Additional file 3: Table S3 siRNA sequences

What problem does this paper attempt to address?

Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma

Zhengyu Yu,Bingquan Qiu,Hui Zhou,Linfeng Li,Ting Niu

DOI: https://doi.org/10.1186/s12935-023-03007-4

IF: 6.429

2023-08-15

Cancer Cell International

Abstract:About 10% of hematologic malignancies are multiple myeloma (MM), an untreatable cancer. Although lactate and branched-chain amino acids (BCAA) are involved in supporting various tumor growth, it is unknown whether they have any bearing on MM prognosis.

oncology
Additional File 11 of A Novel Signature Derived from Metabolism-Related Genes GPT and SMS to Predict Prognosis of Laryngeal Squamous Cell Carcinoma

Yujie Shen,Qiang Huang,Yifan Zhang,Chi‐Yao Hsueh,Liang Zhou

DOI: https://doi.org/10.6084/m9.figshare.20279354

2022-01-01

Abstract:Additional file 11: Table S5. Enrichment analysis of sub-networks.
Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Jie Wang,Jian-ping Hao,Rong Chen,Yun-xia Xiang,Dai-qin Xiong,Yun Wu,Md. Nazim Uddin

DOI: https://doi.org/10.3389/fgene.2021.723001

IF: 3.7

2021-10-29

Frontiers in Genetics

Abstract:Background: Acute Myeloid Leukemia (AML) is a complex and heterogeneous hematologic malignancy. However, the function of prognosis-related signature genes in AML remains unclear. Methods: In the current study, transcriptome sequencing was performed on 15 clinical samples, differentially expressed RNAs were identified using R software. The potential interactions network was constructed by using the common genes between target genes of differentially expressed miRNAs with transcriptome sequencing results. Functional and pathway enrichment analysis was performed to identify candidate gene-mediated aberrant signaling pathways. Hub genes were identified by the cytohubba plugin in Cytoscape software, which then expanded the potential interactions regulatory module for hub genes. TCGA-LAML clinical data were used for the prognostic analysis of the hub genes in the regulatory network, and GVSA analysis was used to identify the immune signature of prognosis-related hub genes. qRT-PCR was used to verify the expression of hub genes in independent clinical samples. Results: We obtained 1,610 differentially expressed lncRNAs, 233 differentially expressed miRNAs, and 2,217 differentially expressed mRNAs from transcriptome sequencing. The potential interactions network is constructed by 12 lncRNAs, 25 miRNAs, and 692 mRNAs. Subsequently, a sub-network including 15 miRNAs as well as 12 lncRNAs was created based on the expanded regulatory modules of 25 key genes. The prognostic analysis results show that CCL5 and lncRNA UCA1 was a significant impact on the prognosis of AML. Besides, we found three potential interactions networks such as lncRNA UCA1 /hsa-miR-16-5p/ COL4A5 , lncRNA UCA1 /hsa-miR-16-5p/ SPARC , and lncRNA SNORA27 /hsa-miR-17-5p/ CCL5 may play an important role in AML. Furthermore, the evaluation of the immune infiltration shows that CCL5 is positively correlated with various immune signatures, and lncRNA UCA1 is negatively correlated with the immune signatures. Finally, the result of qRT-PCR showed that CCL5 is down-regulated and lncRNA UCA1 is up-regulated in AML samples separately. Conclusions: In conclusion, we propose that CCL5 and lncRNA UCA1 could be recognized biomarkers for predicting survival prognosis based on constructing competing endogenous RNAs in AML, which will provide us novel insight into developing novel prognostic, diagnostic, and therapeutic for AML.

genetics & heredity
A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma

Bingxin Zhang,Quanqiang Wang,Zhili Lin,Ziwei Zheng,Shujuan Zhou,Tianyu Zhang,Dong Zheng,Zixing Chen,Sisi Zheng,Yu Zhang,Xuanru Lin,Rujiao Dong,Jingjing Chen,Honglan Qian,Xudong Hu,Yan Zhuang,Qianying Zhang,Zhouxiang Jin,Songfu Jiang,Yongyong Ma

DOI: https://doi.org/10.3389/fcell.2023.1198949

IF: 5.5

2023-06-02

Frontiers in Cell and Developmental Biology

Abstract:Background: Metabolic reprogramming is an important hallmark of cancer. Glycolysis provides the conditions on which multiple myeloma (MM) thrives. Due to MM's great heterogeneity and incurability, risk assessment and treatment choices are still difficult. Method: We constructed a glycolysis-related prognostic model by Least absolute shrinkage and selection operator (LASSO) Cox regression analysis. It was validated in two independent external cohorts, cell lines, and our clinical specimens. The model was also explored for its biological properties, immune microenvironment, and therapeutic response including immunotherapy. Finally, multiple metrics were combined to construct a nomogram to assist in personalized prediction of survival outcomes. Results: A wide range of variants and heterogeneous expression profiles of glycolysis-related genes were observed in MM. The prognostic model behaved well in differentiating between populations with various prognoses and proved to be an independent prognostic factor. This prognostic signature closely coordinated with multiple malignant features such as high-risk clinical features, immune dysfunction, stem cell-like features, cancer-related pathways, which was associated with the survival outcomes of MM. In terms of treatment, the high-risk group showed resistance to conventional drugs such as bortezomib, doxorubicin and immunotherapy. The joint scores generated by the nomogram showed higher clinical benefit than other clinical indicators. The in vitro experiments with cell lines and clinical subjects further provided convincing evidence for our study. Conclusion: We developed and validated the utility of the MM glycolysis-related prognostic model, which provides a new direction for prognosis assessment, treatment options for MM patients.

cell biology,developmental biology
Characterization of a Lactate Metabolism-Related Signature for Evaluation of Immune Features and Prediction Prognosis in Glioma.

Zhiqiang Wu,Jing Wang,Yanan Li,Jianmin Liu,Zijian Kang,Wangjun Yan

DOI: https://doi.org/10.3389/fneur.2022.1064349

IF: 3.4

2023-01-01

Frontiers in Neurology

Abstract:Background:Glioma is one of the most typical tumors in the central nervous system with a poor prognosis, and the optimal management strategy remains controversial. Lactate in the tumor microenvironment is known to promote cancer progression, but its impact on clinical outcomes of glioma is largely unknown.Methods:Glioma RNA-seq data were obtained from TCGA and GCGA databases. Lactate metabolism genes (LMGs) were then evaluated to construct an LMG model in glioma using Cox and LASSO regression. Immune cell infiltration, immune checkpoint gene expression, enriched pathways, genetic alteration, and drug sensitivity were compared within the risk subgroups. Based on the risk score and clinicopathological features, a nomogram was developed to predict prognosis in patients with glioma.Results:Five genes (LDHA, LDHB, MRS2, SL16A1, and SL25A12) showed a good prognostic value and were used to construct an LMG-based risk score. This risk score was shown as an independent prognostic factor with good predictive power in both training and validation cohorts (p < 0.001). The LMG signature was found to be correlated with the expression of immune checkpoint genes and immune infiltration and could shape the tumor microenvironment. Genetic alteration, dysregulated metabolism, and tumorigenesis pathways could be the underlying contributing factors that affect LMG risk stratification. The patients with glioma in the LMG high-risk group showed high sensitivity to EGFR inhibitors. In addition, our nomogram model could effectively predict overall survival with an area under the curve value of 0.894.Conclusion:We explored the characteristics of LMGs in glioma and proposed an LMG-based signature. This prognostic model could predict the survival of patients with glioma and help clinical oncologists plan more individualized and effective therapeutic regimens.
Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Luya Cai,Chuan Hu,Shanshan Yu,Lixiao Liu,Xiaobo Yu,Jiahua Chen,Xuan Li,Fan Liu,Cheng Zhang,Wenfeng Li,Xiaojian Yan

DOI: https://doi.org/10.6084/m9.figshare.13279625

2020-01-01

Abstract:Additional file 2: Table S2. The clinical information of 273 patients with CC from the UCSC database.
One-lincRNA and Five-Mrna Based Signature for Prognosis of Multiple Myeloma Patients Undergoing Proteasome Inhibitors Therapy

Yunhe Liu,Ning Yang,Xueqing Peng,Gang Liu,Hua Zhong,Lei Liu

DOI: https://doi.org/10.1016/j.biopha.2019.109254

IF: 7.419

2019-01-01

Biomedicine & Pharmacotherapy

Abstract:Multiple myeloma is the second largest malignant tumor of the blood system. Proteasome inhibitors (PIs) currently are effective drugs for some myeloma patients, but their prognosis varies. We extracted the transcriptome expression data and clinical information of myeloma patients from MMRF CoMMpass database, and used the Random Survival Forest Variable Hunting (RSF-VH) algorithm to select 6 highly prognosis-related genes and to develop a 6-genes scoring model, by which the risk score predicted were significantly associated with the progress-free survival (PFS, P<0.001). The median PFS of the high-risk group is 21 months, while it is 29 months in the low-risk group. The scoring model was further validated in the testing cohort. Furthermore, Analysis revealed that the risk score performed better in predicting the multiple myeloma patients' prognosis than the existed staging system, including R-ISS. The risk score is independent with the most existed clinical risk indicators, and the prognostic effectiveness of 6-genes scoring model is homogenous in patients with different clinical observations. Further bioinformatic analysis revealed that the risk score is not only significantly associated with multiple myeloma-related pathways, including immune response, but also with the infiltration of many kinds of immune cells that associated with clinical malignancy. Collectively, the model we developed using one lincRNA and five mRNAs is a robust and effective indicator for myeloma patients' prognosis undergoing proteasome inhibitors therapy.
Construction of mitochondrial quality regulation genes‐related prognostic model based on bulk‐RNA‐seq analysis in multiple myeloma

Xiaohui Li,Ling Zhang,Chengcheng Liu,Yi He,Xudong Li,Yichuan Xu,Cuiyin Gu,Xiaozhen Wang,Shuoting Wang,Jingwen Zhang,Jiajun Liu

DOI: https://doi.org/10.1002/biof.2135

2024-10-26

BioFactors

Abstract:We described the mitochondrial quality regulation gene‐related features and developed a reliable prognostic risk model and nomogram tool; our findings will promote the understanding of occurrence of disease in multiple myeloma. Mitochondrial quality regulation plays an important role in affecting the treatment sensitivity of multiple myeloma (MM). We aimed to develop a mitochondrial quality regulation genes (MQRGs)‐related prognostic model for MM patients. The Genomic Data Commons‐MM of bulk RNA‐seq, mutation, and single‐cell RNA‐seq (scRNA‐seq) dataset were downloaded, and the MQRGs gene set was collected previous study. "maftools" and CIBERSORT were used for mutation and immune‐infiltration analysis. Subsequently, the "ConsensusClusterPlus" was used to perform the unsupervised clustering analysis, "survminer" and "ssGSEA" R package was used for the Kaplan–Meier survival and enrichment analysis, "limma" R, univariate and Least Absolute Shrinkage and Selection Operator Cox were used for RiskScore model. The "timeROC" R package was used for Receiver Operating Characteristic Curve analysis. Finally, the "Seurat" R package was used for scRNA‐seq analysis. These MQRGs are mainly located on chromosome‐1,2,3,7, and 22 and had significant expression differences among age, gender, and stage groups, in which PPARGC1A and PPARG are the high mutation genes. Most MQRGs expression are closely associated with the plasma cells infiltration and can divide the patients into 2 different prognostic clusters (C1, C2). Then, 8 risk models were screened from 60 DEGs for RiskScore, which is an independent prognostic factor and effectively divided the patients into high and low risk groups with significant difference of immune checkpoint expression. Nomogram containing RiskScore can accurately predict patient prognosis, and a series of specific transcription factor PRDM1 and IRF1 were identified. We described the based molecular features and developed a high effective MQRGs‐related prognostic model in MM.

biochemistry & molecular biology,endocrinology & metabolism
Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification

Cheng Sun,Wanqiu Zhang,Hao Liu,Yangyang Ding,Jingjing Guo,Shudao Xiong,Zhimin Zhai,Wei Hu

DOI: https://doi.org/10.1038/s41598-024-65937-x

2024-07-02

Abstract:Multiple myeloma (MM) is an incurable hematological malignancy with poor survival. Accumulating evidence reveals that lactylation modification plays a vital role in tumorigenesis. However, research on lactylation-related genes (LRGs) in predicting the prognosis of MM remains limited. Differentially expressed LRGs (DELRGs) between MM and normal samples were investigated from the Gene Expression Omnibus database. Univariate Cox regression and LASSO Cox regression analysis were applied to construct gene signature associated with overall survival. The signature was validated in two external datasets. A nomogram was further constructed and evaluated. Additionally, Enrichment analysis, immune analysis, and drug chemosensitivity analysis between the two groups were investigated. qPCR and immunofluorescence staining were performed to validate the expression and localization of PFN1. CCK-8 and flow cytometry were performed to validate biological function. A total of 9 LRGs (TRIM28, PPIA, SOD1, RRP1B, IARS2, RB1, PFN1, PRCC, and FABP5) were selected to establish the prognostic signature. Kaplan-Meier survival curves showed that high-risk group patients had a remarkably worse prognosis in the training and validation cohorts. A nomogram was constructed based on LRGs signature and clinical characteristics, and showed excellent predictive power by calibration curve and C-index. Moreover, biological pathways, immunologic status, as well as sensitivity to chemotherapy drugs were different between high- and low-risk groups. Additionally, the hub gene PFN1 is highly expressed in MM, knocking down PFN1 induces cell cycle arrest, suppresses cell proliferation and promotes cell apoptosis. In conclusion, our study revealed that LRGs signature is a promising biomarker for MM that can effectively early distinguish high-risk patients and predict prognosis.
Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma

Licheng Li,Ting Chen,Jishi Wang,Mengxing Li,Qinshan Li

DOI: https://doi.org/10.1155/2022/3922739

IF: 4.4929

2022-01-01

Journal of Immunology Research

Abstract:Myeloma (MM) is a malignant plasma cell disorder, which is incurable owing to its drug resistance. Autophagy performs an integral function in homeostasis, survival, and drug resistance in multiple myeloma (MM). Therefore, the purpose of the present research was to identify potential autophagy-related genes (ARGs) in patients with MM. We downloaded the transcriptomic data (GSE136400) of patients with MM, as well as the corresponding clinical data from the Gene Expression Omnibus (GEO); the patients were classified at random into two groups in a ratio of 6: 4, with 212 samples in the training dataset and 142 samples in the test dataset. Both multivariate and univariate Cox regression analyses were performed to identify autophagy-related genes. The univariate Cox regression analysis demonstrated that 26 ARGs had a significant correlation with overall survival (OS). We constructed an autophagy-related risk prognostic model based on six ARGs: EIF2AK2 (ENSG00000055332), KIF5B (ENSG00000170759), MYC (ENSG00000136997), NRG2 (ENSG00000158458), PINK1 (ENSG00000158828), and VEGFA (ENSG00000112715) using LASSO-Cox regression analysis to predict risk outcomes, which revealed substantially shortened OS duration in the high-risk cohort in contrast with that in the low-risk cohort. Therefore, the ARG-based model significantly predicted the MM patients’ prognoses and was verified in an internal test set. Differentially expressed genes were found to be predominantly enriched in pathways associated with inflammation and immune regulation. Immune infiltration of tumor cells resulted in the formation of a strong immunosuppressive microenvironment in high-risk patients. The potential therapeutic targets of ARGs were subsequently analyzed via protein–drug network analysis. Therefore, a prognostic model for MM was established via a comprehensive analysis of ARGs, through using the clinical models; we have further revealed the molecular landscape features of multiple myeloma.
Additional File 2 of Prognostic Role of METTL1 in Glioma

Lun Li,Yi Yang,Zhenshuang Wang,Cheng‐Ran Xu,Jinhai Huang,G. Q. Li

DOI: https://doi.org/10.6084/m9.figshare.17088407

2021-01-01

Abstract:Additional file 2. DNA sequencing results from all the samples.
An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature

Zhengyu Yu,Bingquan Qiu,Linfeng Li,Jing Xu,Hui Zhou,Ting Niu

DOI: https://doi.org/10.3389/fonc.2022.992387

IF: 4.7

2022-08-30

Frontiers in Oncology

Abstract:Multiple myeloma (MM), a hematologic malignancy, is characterized by malignant plasma cells clonal proliferation. Many evidences indicated the indirect interaction between hypoxic environment and immune state in MM tumorigenesis, but the underlying mechanism remains unclear. MM-related datasets were downloaded from the Gene Expression Omnibus (GEO) database. The R packages were applied for screening protective differentially expressed genes (DEGs) and risk DEGs. The signature was constructed based the most prognostic gene signature in the training and assessed in the validation cohorts. The immune cell infiltration, the expression of the HLA family and immune checkpoint genes inside the low- and high-risk groups were compared to determine the differences in immune infiltration and immunotherapy responses. Moreover, the expression of HLA families and immune checkpoints inside the low- and high-risk groups was markedly disordered. The results indicated hypoxia- and immune-related genes, including CHRDL1 , DDIT4 , DNTT , FAM133A , MYB , PRR15 , QTRT1 , and ZNF275 , were identified and used to construct a prognostic signature. Role of DDIT4 in multiple myeloma was confirmed in vivo and in vitro . DDIT4 knockdown inhibited MM cell viability, migration and invasion potential as well as promoted myeloma cells apoptosis under hypoxia. Taken together, our study may contribute to the treatment and prognosis prediction of MM.

oncology
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia

Yun Liu,Teng Li,Hongling Zhang,Lijuan Wang,Rongxuan Cao,Junying Zhang,Jing Liu,Liping Liu

DOI: https://doi.org/10.1016/j.heliyon.2024.e31249

IF: 3.776

2024-05-15

Heliyon

Abstract:Background: Acute myeloid leukemia (AML) is a malignant clonal proliferative disease of hematopoietic system. Despite tremendous progress in uncovering the AML genome, only a small number of mutations have been incorporated into risk stratification and used as therapeutic targets. In this research, we performed to construct a predictive prognosis risk model for AML patients according to gene mutations. Methods: Next-generation sequencing (NGS) technology was utilized to detect gene mutation from 118 patients. mRNA expression profiles and related clinical information were mined from TCGA and GEO databases. Consensus cluster analysis was applied to obtain molecular subtypes, and differences in clinicopathological features, prognosis, and immune microenvironment of different clusters were systematically compared. According to the differentially expressed genes (DEGs) between clusters, univariate and LASSO regression analysis were applied to identify gene signatures to build a prognostic risk model. Patients were classified into high-risk (HR) and low-risk (LR) groups according to the median risk score (RS). Differences in prognosis, immune profile, and therapeutic sensitivity between two groups were analyzed. The independent predictive value of RS was assessed and a nomogram was developed. Results: NGS detected 24 mutated genes, with higher mutation frequencies in CBL (63 %) and SETBP1 (49 %). Two clusters exhibited different immune microenvironments and survival probability (p = 0.0056) were identified. A total of 444 DEGs were screened in two clusters, and a mutation-associated risk model was constructed, including MPO, HGF, SH2B3, SETBP1, HLA-DRB1, LGALS1, and KDM5B. Patients in LR had a superior survival time compared to HR. Predictive performance of this model was confirmed and the developed nomogram further improved the applicability of the risk model with the AUCs for predicting 1-, 3-, 5-year survival rate were 0.829, 0.81 and 0.811, respectively. HR cases were more sensitive to erlotinib, CI-1040, and AZD6244. Conclusion: These findings supplemented the understanding of gene mutations in AML, and constructed models had good application prospect to provide effective information for predicting prognosis and treatment response of AML.
A novel risk score model of lactate metabolism for predicting outcomes and immune signatures in acute myeloid leukemia

Ze-min Huang,Jing Wei,Xiao-wen Pan,Xing-biao Chen,Zi-yuan Lu

DOI: https://doi.org/10.1038/s41598-024-76919-4

IF: 4.6

2024-10-30

Scientific Reports

Abstract:Acute myeloid leukemia (AML) is a malignant tumor with high recurrence and refractory rates and low survival rates. Increased glycolysis is characteristic of metabolism in AML blast cells and is also associated with chemotherapy resistance. The purpose of this study was to use gene expression and clinical information from The Cancer Genome Atlas (TCGA) database to identify subtypes of AML associated with lactate metabolism. Two different subtypes linked to lactate metabolism, each with specific immunological features and consequences for prognosis, were identified in this study. Using the TCGA and International Cancer Genome Consortium (GEO) cohorts, a prognostic model composed of genes (LMNA, RETN and HK1) for the prognostic value of the lactate metabolism-related risk score prognostic model was created and validated, suggesting possible therapeutic uses. Additionally, the diagnostic value of the prognostic model genes was explored. LMNA and HK1 were ultimately identified as hub genes, and their roles in AML were determined through immune infiltration, GeneMANIA, GSEA, methylation analysis and single-cell analysis. LMNA was upregulated in AML associating with a poor prognosis while HK1 was downregulated in AML associating with a favorable prognosis. The findings underscore the noteworthy impact of genes linked to lactate metabolism in AML and illustrate the possible therapeutic usefulness of the lactate metabolism-related risk score and the hub lactate metabolism-related genes in guiding AML patients' treatment choices.

multidisciplinary sciences
Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma

Jing Wang,Lili Guo,Chenglan Lv,Min Zhou,Yuan Wan

DOI: https://doi.org/10.3389/fonc.2023.1105196

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:BackgroundMultiple myeloma (MM) remains an essentially incurable disease. This study aimed to establish a predictive model for estimating prognosis in newly diagnosed MM based on gene expression profiles. MethodsRNA-seq data were downloaded from the Multiple Myeloma Research Foundation (MMRF) CoMMpass Study and the Genotype-Tissue Expression (GTEx) databases. Weighted gene coexpression network analysis (WGCNA) and protein-protein interaction network analysis were performed to identify hub genes. Enrichment analysis was also conducted. Patients were randomly split into training (70%) and validation (30%) datasets to build a prognostic scoring model based on the least absolute shrinkage and selection operator (LASSO). CIBERSORT was applied to estimate the proportion of 22 immune cells in the microenvironment. Drug sensitivity was analyzed using the OncoPredict algorithm. ResultsA total of 860 newly diagnosed MM samples and 444 normal counterparts were screened as the datasets. WGCNA was applied to analyze the RNA-seq data of 1589 intersecting genes between differentially expressed genes and prognostic genes. The blue module in the PPI networks was analyzed with Cytoscape, and 10 hub genes were identified using the MCODE plug-in. A three-gene (TTK, GINS1, and NCAPG) prognostic model was constructed. This risk model showed remarkable prognostic value. CIBERSORT assessment revealed the risk model to be correlated with activated memory CD4 T cells, M0 macrophages, M1 macrophages, eosinophils, activated dendritic cells, and activated mast cells. Furthermore, based on OncoPredict, high-risk MM patients were sensitive to eight drugs. ConclusionsWe identified and constructed a three-gene-based prognostic model, which may provide new and in-depth insights into the treatment of MM patients.
Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma

Tanlun Zeng,Sihan Jiang,Yichuan Wang,Guanqun Sun,Jinjin Cao,Dingtao Hu,Guang Wang,Xijun Liang,Jin Ding,Juan Du

DOI: https://doi.org/10.1080/15384101.2023.2213926

2023-05-27

Cell Cycle

Abstract:Multiple myeloma (MM) is the second most common hematologic malignancy, which primarily occurs in the elderly. Cellular senescence is considered to be closely associated with the occurrence and progression of malignant tumors including MM, and lncRNA can mediate the process of cellular senescence by regulating key signaling pathways such as p53/p21 and p16/RB. However, the role of cellular senescence related lncRNAs (CSRLs) in MM development has never been reported. Herein, we identified 11 CSRLs (AC004918.5, AC103858.1, AC245100.4, ACBD3-AS1, AL441992.2, ATP2A1-AS1, CCDC18-AS1, LINC00996, TMEM161B-AS1, RP11-706O15.1, and SMURF2P1) to build the CSRLs risk model, which was confirmed to be highly associated with overall survival (OS) of MM patients. We further demonstrated the strong prognostic value of the risk model in MM patients receiving different regimens, especially for those with three-drug combination of bortezomib, lenalidomide, and dexamethasone (VRd) as first-line therapy. Not only that, our risk model also excels in predicting the OS of MM patients at 1, 2, and 3 years. In order to verify the function of these CSRLs in MM, we selected the lncRNA ATP2A1-AS1 which presented the largest expression difference between high-risk groups and low-risk groups for subsequent analysis and validation. Finally, we found that down-regulation of ATP2A1-AS1 can promote cellular senescence in MM cell lines. In conclusion, the CSRLs risk model established in present study provides a novel and more accurate method for predicting MM patients' prognosis and identifies a new target for MM therapeutic intervention.

cell biology
A Network Analysis of Multiple Myeloma Related Gene Signatures.

Yu Liu,Haocheng Yu,Seungyeul Yoo,Eunjee Lee,Alessandro Lagana,Samir Parekh,Eric E. Schadt,Li Wang,Jun Zhu

DOI: https://doi.org/10.3390/cancers11101452

2019-01-01

Cancers

Abstract:Multiple myeloma (MM) is the second most prevalent hematological cancer. MM is a complex and heterogeneous disease, and thus, it is essential to leverage omics data from large MM cohorts to understand the molecular mechanisms underlying MM tumorigenesis, progression, and drug responses, which may aid in the development of better treatments. In this study, we analyzed gene expression, copy number variation, and clinical data from the Multiple Myeloma Research Consortium (MMRC) dataset and constructed a multiple myeloma molecular causal network (M3CN). The M3CN was used to unify eight prognostic gene signatures in the literature that shared very few genes between them, resulting in a prognostic subnetwork of the M3CN, consisting of 178 genes that were enriched for genes involved in cell cycle (fold enrichment = 8.4, p value = 6.1 × 10−26). The M3CN was further used to characterize immunomodulators and proteasome inhibitors for MM, demonstrating the pleiotropic effects of these drugs, with drug-response signature genes enriched across multiple M3CN subnetworks. Network analyses indicated potential links between these drug-response subnetworks and the prognostic subnetwork. To elucidate the structure of these important MM subnetworks, we identified putative key regulators predicted to modulate the state of these subnetworks. Finally, to assess the predictive power of our network-based models, we stratified MM patients in an independent cohort, the MMRF-CoMMpass study, based on the prognostic subnetwork, and compared the performance of this subnetwork against other signatures in the literature. We show that the M3CN-derived prognostic subnetwork achieved the best separation between different risk groups in terms of log-rank test p-values and hazard ratios. In summary, this work demonstrates the power of a probabilistic causal network approach to understanding molecular mechanisms underlying the different MM signatures.
Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer

Yin-wei Dai,Zhi-kai Wen,Zhi-xuan Wu,Hao-dong Wu,Lin-xi Lv,Cong-zhi Yan,Cong-hui Liu,Zi-qiong Wang,Chen Zheng

DOI: https://doi.org/10.3389/fgene.2022.880387

IF: 3.7

2022-05-13

Frontiers in Genetics

Abstract:Background and Purpose: Breast cancer (BRCA) is the most frequent female malignancy and is potentially life threatening. The amino acid metabolism (AAM) has been shown to be strongly associated with the development and progression of human malignancies. In turn, long noncoding RNAs (lncRNAs) exert an important influence on the regulation of metabolism. Therefore, we attempted to build an AAM-related lncRNA prognostic model for BRCA and illustrate its immune characteristics and molecular mechanism. Experimental Design: The RNA-seq data for BRCA from the TCGA-BRCA datasets were stochastically split into training and validation cohorts at a 3:1 ratio, to construct and validate the model, respectively. The amino acid metabolism-related genes were obtained from the Molecular Signature Database. A univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression, and a multivariate Cox analysis were applied to create a predictive risk signature. Subsequently, the immune and molecular characteristics and the benefits of chemotherapeutic drugs in the high-risk and low-risk subgroups were examined. Results: The prognostic model was developed based on the lncRNA group including LIPE-AS1, AC124067.4, LINC01655, AP005131.3, AC015802.3, USP30-AS1, SNHG26, and AL589765.4. Low-risk patients had a more favorable overall survival than did high-risk patients, in accordance with the results obtained for the validation cohort and the complete TCGA cohort. The elaborate results illustrated that a low-risk index was correlated with DNA-repair–associated pathways; a low TP53 and PIK3CA mutation rate; high infiltration of CD4 + T cells, CD8 + T cells, and M1 macrophages; active immunity; and less-aggressive phenotypes. In contrast, a high-risk index was correlated with cancer and metastasis-related pathways; a high PIK3CA and TP53 mutation rate; high infiltration of M0 macrophages, fibroblasts, and M2 macrophages; inhibition of the immune response; and more invasive phenotypes. Conclusion: In conclusion, we attempted to shed light on the importance of AAM-associated lncRNAs in BRCA. The prognostic model built here might be acknowledged as an indispensable reference for predicting the outcome of patients with BRCA and help identify immune and molecular characteristics.

genetics & heredity
A novel amino acid metabolism-related gene risk signature for predicting prognosis in clear cell renal cell carcinoma

Jiaqi Su,Xi Tian,Zihao Zhang,Wenhao Xu,Aihetaimujiang Anwaier,Shiqi Ye,Shuxuan Zhu,Yue Wang,Guohai Shi,Yuanyuan Qu,Hailiang Zhang,Dingwei Ye

DOI: https://doi.org/10.3389/fonc.2022.1019949

IF: 4.7

2022-10-14

Frontiers in Oncology

Abstract:Background Renal cancer is one of the most lethal cancers because of its atypical symptoms and metastatic potential. The metabolism of amino acids and their derivatives is essential for cancer cell survival and proliferation. Thus, the construction of the amino acid metabolism-related risk signature might enhance the accuracy of the prognostic model and shed light on the treatments of renal cancers. Methods RNA expression and clinical data were downloaded from Santa Cruz (UCSC) Xena, GEO, and ArrayExpress databases. The “DESeq2” package identified the differentially expressed genes. Univariate COX analysis selected prognostic genes related to the metabolism of amino acids. Patients were divided into two clusters using the “ConsensusClusterPlus” package, and the CIBERSORT, ESTIMATE methods were explored to assess the immune infiltrations. The LASSO regression analysis constructed a risk model which was evaluated the prediction accuracy in two independent cohorts. The genomic alterations and drug sensitivity of 18-LASSO-genes were assessed. The differentially expressed genes between two clusters were used to perform functional enrichment analysis and weighted gene co-expression network analysis (WGCNA). Furthermore, external validation of TMEM72 expression was conducted in the FUSCC cohort containing 33 ccRCC patients. Results The amino acid metabolism-related genes had significant correlations with prognosis. The patients in Cluster A demonstrated better survival, lower Treg cell proportion, higher ESTIMATE scores, and higher cuproptosis-related gene expressions. Amino acid metabolism-related genes with prognostic values were used to construct a risk model and patients in the low risk group were associated with improved outcomes. The Area Under Curve of the risk model was 0.801, 0.777, and 0.767 at the first, second, and third year respectively. The external validation cohort confirmed the stable prognostic value of the risk model. WGCNA identified four gene modules correlated with immune cell infiltrations and cuproptosis. We found that TMEM72 was downregulated in tumors by using TCGA, GEO datasets (p<0.001) and the FUSCC cohort (p=0.002). Conclusion Our study firstly constructed an 18 amino acid metabolism related signature to predict the prognosis in clear cell renal cell carcinoma. We also identified four potential gene modules potentially correlated with cuproptosis and identified TMEM72 downregulation in ccRCC which deserved further studies.

oncology
Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma

Wei Wang,Shi-wen Xu,Xia-yin Zhu,Qun-yi Guo,Min Zhu,Xin-li Mao,Ya-Hong Chen,Shao-wei Li,Wen-da Luo

DOI: https://doi.org/10.3389/fgene.2021.665173

IF: 3.7

2021-04-26

Frontiers in Genetics

Abstract:Background Multiple myeloma (MM) is a malignant hematopoietic disease that is usually incurable. RNA-binding proteins (RBPs) are involved in the development of many tumors, but their prognostic significance has not been systematically described in MM. Here, we developed a prognostic signature based on eight RBP-related genes to distinguish MM cohorts with different prognoses. Method After screening the differentially expressed RBPs, univariate Cox regression was performed to evaluate the prognostic relevance of each gene using The Cancer Genome Atlas (TCGA)-Multiple Myeloma Research Foundation (MMRF) dataset. Lasso and stepwise Cox regressions were used to establish a risk prediction model through the training set, and they were validated in three Gene Expression Omnibus (GEO) datasets. We developed a signature based on eight RBP-related genes, which could classify MM patients into high- and low-score groups. The predictive ability was evaluated using bioinformatics methods. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and gene set enrichment analyses were performed to identify potentially significant biological processes (BPs) in MM. Result The prognostic signature performed well in the TCGA-MMRF dataset. The signature includes eight hub genes: HNRNPC , RPLP2 , SNRPB , EXOSC8 , RARS2 , MRPS31 , ZC3H6 , and DROSHA . Kaplan–Meier survival curves showed that the prognosis of the risk status showed significant differences. A nomogram was constructed with age; B2M , LDH , and ALB levels; and risk status as prognostic parameters. Receiver operating characteristic (ROC) curve, C-index, calibration analysis, and decision curve analysis (DCA) showed that the risk module and nomogram performed well in 1, 3, 5, and 7-year overall survival (OS). Functional analysis suggested that the spliceosome pathway may be a major pathway by which RBPs are involved in myeloma development. Moreover, our signature can improve on the R-International Staging System (ISS)/ISS scoring system (especially for stage II), which may have guiding significance for the future. Conclusion We constructed and verified the 8-RBP signature, which can effectively predict the prognosis of myeloma patients, and suggested that RBPs are promising biomarkers for MM.

genetics & heredity

Additional File 3 of Characterization and Application of a Lactate and Branched Chain Amino Acid Metabolism Related Gene Signature in a Prognosis Risk Model for Multiple Myeloma

Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma

Additional File 11 of A Novel Signature Derived from Metabolism-Related Genes GPT and SMS to Predict Prognosis of Laryngeal Squamous Cell Carcinoma

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma

Characterization of a Lactate Metabolism-Related Signature for Evaluation of Immune Features and Prediction Prognosis in Glioma.

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

One-lincRNA and Five-Mrna Based Signature for Prognosis of Multiple Myeloma Patients Undergoing Proteasome Inhibitors Therapy

Construction of mitochondrial quality regulation genes‐related prognostic model based on bulk‐RNA‐seq analysis in multiple myeloma

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification

Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma

Additional File 2 of Prognostic Role of METTL1 in Glioma

An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature

Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia

A novel risk score model of lactate metabolism for predicting outcomes and immune signatures in acute myeloid leukemia

Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma

Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma

A Network Analysis of Multiple Myeloma Related Gene Signatures.

Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer

A novel amino acid metabolism-related gene risk signature for predicting prognosis in clear cell renal cell carcinoma

Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma